This is a "connection" page, showing publications co-authored by Timothy Pardee and David Caudell.
Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS. The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. PLoS One. 2017; 12(6):e0179798.
Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol. 2016 Sep; 12(17):2009-20.
Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget. 2014 Jun 30; 5(12):4170-9.
Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leuk Res. 2013 Jan; 37(1):112-6.
Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP results in high efficacy against AML and low toxicity. Blood. 2012 Apr 12; 119(15):3561-70.